Lentivirus Packaging Service

Overview Service Details Case Study Contact US

Home » Cell Engineering » Lentivirus Packaging Service

Overview

Lentiviral vectors, derived from the human immunodeficiency virus type 1 (HIV-1), are powerful and efficient gene delivery tools. They are capable of efficiently transducing both dividing and non-dividing cells, such as neurons and stem cells. By integrating target gene into the host genome, they enable stable and long-term target gene expression—making them essential in gene therapy, cell therapy, and vaccine development.

GenScript utilizes a third-generation self-inactivating (SIN) lentiviral system to provide a one-stop lentivirus packaging service—from vector design to virus packaging and purification. Our advanced serum-free suspension culture technology, combined with optimized vector pGS-LVV, guarantees high-titer lentivirus production up to 10⁹ TU/mL. GenScript proprietary lentivirus packaging platform delivers high-quality lentivirus with industry-leading turnaround times—just 5 business days from plasmid to lentivirus.

Cell Engineering

Service Highlights

5 BDs
to Lentivirus Packaging

10 BDs from gene to lentivirus

1E+8 TU/mL
Guaranteed Functional Titer

Average delivered titer 3 times higher than guaranteed

>10Kb Large Insert
Maximum 400% Titer Boost

Proprietary lentivirus platform for large insert with unmatched efficiency

100% Accuracy
Functional Titer

Exclusive Default QC - Duplex qPCR

Talk With Our Expert

Order Now

Request Now

General Workflow

Service Details

Scale	Application	Guaranteed Functional Titer ^ⓘ	Volume	TAT	Default QC	Deliverable
Purified	Cell Culture	>1E+8 TU/mL	0.1 mL 1 mL 5 mL	Starting at 7 business days	Duplex qPCR Mycoplasma test Transduction test (Fluorescent protein only) Sterility Test (Internal test)	Customized lentivirus Control lentivirus^Free Polybrene^Free
Purified		>1E+9 TU/mL	1mL	Starting at 7 business days
Supernatant		>2E+6 TU/mL	0.2 mL	Starting at 5 business days	P24 ELISA Mycoplasma Test	Customized lentivirus supernatant
Ultra-purified	In Vivo Animal Study	>1E+8 TU/mL	1 mL 2 mL 5 mL 10 mL	Starting at 12 business days	Duplex qPCR Mycoplasma test Transduction test (Fluorescent protein only) Sterility Test (Internal test)	Customized lentivirus
Ultra-purified	In Vivo Animal Study	>1E+9 TU/mL	0.5 mL 1 mL	Starting at 12 business days		Customized lentivirus

Note:
P24 ELISA: Quantify capsid proteins, measures the total number of viral particles (physical titer). The calculated functional titer (TU/mL) is derived from the P24 titer equation and represents a predicted value, which may differ from actual functional titers.
Duplex qPCR: Directly measure and quantify the infectious viral particles capable of transducing target cells, providing precise functional titer.

QC Control

Vector Recommendation

#	Vector Name	Application	Promoter	Antibiotics Marker	Fluorescence Marker

Case Study

Case Study 1: Transduction Test

Bright Field	Fluorescence Field
		Positive control MOI = 2 (by qPCR titration)
		Sample 1 LTR Insert Length: >9 kb Duplex qPCR Titer: 2.52×10^8 TU/mL MOI = 1.5 (by qPCR titration)
		Sample 2 - 1μL LTR Insert Length: >9 kb Duplex qPCR Titer: 2.06×10^8 TU/mL MOI = 1.5 (by qPCR titration)

Case Study 2: Efficient CAR-T Generation in PBMC Transduction

Challenge: Primary cells are difficult to transduce due to their non-dividing nature. And the downstream application (CAR-T therapy) required high transduction efficiency at a low MOI.

Solution: Built on our proprietary lentiviral packaging system and pGS-LVV vector, we optimized the transfection workflow with production boosters to deliver lentiviral vector with high functional titer.

Lentiviral Vector: pGS-LVV-EF1a-CD19CAR-T2A-EGFP

Result: Delivered lentiviral vector with a functional titer of 7.07×10⁹ TU/mL (duplex qPCR). The lentiviral vector successfully mediated anti-CD19 CAR expression in primary human PBMCs. Even at a low MOI of 1, transduction efficiency exceeded 70%.

Human PBMC	Positive Cells (%) EGFP+/CD19CAR+
Non-transduced	0.0%
MOI=1	72.6%
MOI=2	69.0%
MOI=5	73.0%
MOI=10	71.5%

Case Study 3: Large Insert Lentivirus Performance

Challenge: The oversized insert (>10 kb) compromises lentiviral packaging efficiency, resulting in low viral titer and poor downstream performance.

Solution: Utilizing our proprietary lentivirus packaging system, we optimized each step of virus packaging specialized for large insert
(>6.5 kb) to achieve high-titer delivery.

Result:

Bright Field	Fluorescence Field
		Positive Control 5’ LTR to 3’ LTR: 6,570 bp MOI = 2 (by qPCR titration) Time: 48h after transduction
		Sample 1 5’ LTR to 3’ LTR: 11,288 bp Duplex qPCR Titer: 1.03×10^8 TU/mL MOI = 2 (by qPCR titration) Time: 48h after transduction

Case Study 4: Cas9/gRNA Co-delivery for Knockout Cell Line Development

Challenge: The requirement for co-delivering Cas9 and gRNA resulted in a large insert size, compromising lentiviral packaging efficiency. Additionally, the inherent resistance of macrophages to transduction, driven by their robust antiviral mechanisms, required lentivirus with high functional titers.

Solution: Utilizing our proprietary lentivirus packaging system, we optimized each step of virus packaging specialized for large insert(> 6.5kb) to achieve high-titer delivery.

Result: Delivered Cas9+gRNA lentivirus with a functional titer >1×10⁹ TU/mL, successfully establishing stable cell pools with >90% gene knockout efficiency.

Validation of Knockout Efficiency by Western Blot
Case Study 5: LVV Enables Efficient Expression of a 12-Transmembrane Protein

Background: Multi-transmembrane proteins are challenging to express on the cell surface due to complex folding and membrane integration.

Strategy: Using lentiviral packaging of pGS-LVV-CAG-T-hPGK-PuroR, HEK293T cells were efficiently transduced at MOI 5 and 10.

Results: This approach achieved 100% positive expression of the T (12-transmembrane) protein, with levels exceeding 100-fold above baseline without enrichment, demonstrating that viral delivery enables high-efficiency transduction and robust expression of difficult multi-transmembrane targets.
Case Study 6: Robust In Vivo Gene Expression with ultra-purified LVV

Ultra-purified LVVs achieved successful systemic delivery and sustained transgene expression for at least 7 days in mice, demonstrating potential for in vivo gene delivery applications.

In vivo expression of VSV-G-pseudotyped LVVs in BALB/c mice. In vivo-grade lentiviral vectors expressing firefly luciferase (Fluc) were administered to BALB/c mice by intravenous (IV) injection at doses of 2.0 × 10^7 TU or 5.0 × 10^7 TU per mouse. Fluc expression was monitored by whole-body bioluminescence imaging using an IVIS imaging system.
(A) Quantification of Fluc expression at 24, 72, and 168 hours post-injection.
(B) Representative IVIS images showing the distribution and intensity of Fluc expression in BALB/c mice.